导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.47% | 2938/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -6.98% | 3689/5421 |
| 近一季 | 9.87% | 167/5209 |
| 近半年 | 1.15% | 1078/4920 |
| 近一年 | -14.11% | 3634/4366 |
| 近两年 | 20.63% | 2636/2954 |
| 近三年 | -9.16% | 2021/2253 |
| 成立以来 | 47.99% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.42% 3196/4961 |
-3.58% 3463/5312 |
- - |
- - |
| 2025 | 6.34% 2968/4813 |
1.31% 1652/3635 |
2.31% 1657/4076 |
15.77% 2775/4524 |
-11.39% 4200/4813 |
| 2024 | -12.46% 2380/3463 |
-11.05% 2405/2808 |
-8.58% 2250/3014 |
17.34% 1211/3129 |
-8.26% 2841/3463 |
| 2023 | -11.86% 1430/2656 |
-0.69% 1818/2280 |
-7.62% 1875/2385 |
-1.89% 593/2515 |
-2.07% 420/2655 |
| 2022 | -20.50% 975/2207 |
-13.64% 804/1919 |
0.25% 1571/2016 |
-15.87% 1360/2113 |
9.14% 237/2208 |
| 2021 | -11.22% 1105/1822 |
-3.32% 800/1255 |
12.64% 322/1330 |
-14.10% 1362/1466 |
-5.10% 1505/1822 |
| 2020 | 62.23% 116/1250 |
8.95% 29/1028 |
29.49% 73/1067 |
6.12% 872/1164 |
8.36% 677/1184 |
| 2019 | 41.96% 225/1092 |
27.91% 331/754 |
-4.87% 442/804 |
9.68% 53/850 |
6.38% 616/918 |
| 2018 | -22.85% 261/834 |
- - |
- - |
- - |
-18.98% 661/691 |
| 2017 | 12.50% 273/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.55% 324/605 |
- - |
- - |
- - |
- - |
| 2015 | 43.93% 36/575 |
- - |
- - |
- - |
- - |
| 2014 | 3.84% 228/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰国证医药卫生行业指数A VS. 长安沪深300非周期A(740101) |